A likely tori.

Immune checkpoint inhibition is making a move to the front lines for metastatic nasopharyngeal cancer. The JUPITER-02 trial, presented this week in abstract form, randomized 289 patients with metastatic and/or recurrent nasopharyngeal cancer with no prior chemo in this setting to gem/cis +/- concurrent and maintenance toripalimab, a novel anti-PD-1 agent. The primary endpoint of progression-free survival was increased by 50% from 8 to 12 months with the addition of toripalimab. This benefit held across PD-L1 statuses but was at the cost of significantly more grade 3+ toxicities. Overall survival analysis is not yet mature, though is currently trending towards a likely victory. Now, back to the drug you’ve probably never heard of: toripalimab. What makes tori stand out from its predecessors? Mainly that’s it’s the first of its kind to to hit the mainstream from a Chinese pharmaceutical company, TopAlliance. | Xu, ASCO 2021

Comments

  1. This is another testimony on how Chief Dr Lucky cured my HIV disease. Do you need a cure for your HIV disease? Do you want to be cured from your cancer disease? Or you want to be free from any type of disease. Kindly visit his website https://chiefdrluckyherbaltherapy.wordpress.com/ . He just cured my HIV disease and I’m very grateful to him, he is the only herbalist that can cure you.  
    WhatsApp number : +2348132777335 
    Via Email : chiefdrlucky@gmail.com
    Thank you all for reading,
    God bless"

    ReplyDelete
  2. This has been a really wonderful article. Many thanks for providing this information. Visit our website too girl kubet

    ReplyDelete

Post a Comment

Popular Posts